Can you list diseases targeted by apotex's ruxolitinib?

Ruxolitinib (generic from Apotex) is a JAK1/JAK2 inhibitor. The main disease indications associated with the reference product (Jakafi) and typically covered by Apotex’s version are:

- Myelofibrosis (primary myelofibrosis, and MF secondary to other myeloproliferative neoplasms such as post–polycythemia vera or post–essential thrombocythemia)
- Polycythemia vera in adults with inadequate response to or intolerance of hydroxyurea
- Acute graft-versus-host disease (GVHD) in adults and in pediatric patients aged 12 years and older

Notes:
- Generics are labeled with indications that mirror the reference product’s labeling in the country of approval, but exact wording can vary by country.
- If you want country-specific labeling (e.g., FDA/US, Health Canada, EU), tell me which country you’re interested in and I can outline the exact indications listed there.